OptumRx News: New Approach to Pharmacy Payment

OptumRx is making a significant change to its pharmacy payment approach, which could impact how you pay for your prescriptions. This new approach aims to simplify the payment process and reduce costs for patients.

The company is introducing a new payment model that ties payment to the patient's out-of-pocket costs, rather than the pharmacy's charges. This means that patients will pay a fixed amount for their prescriptions, regardless of the pharmacy's price.

This change is expected to benefit patients who have high out-of-pocket costs for their medications. By reducing the variability in pharmacy prices, patients will know exactly how much they need to pay for their prescriptions.

The new payment model is designed to be more transparent and predictable, giving patients more control over their prescription costs.

See what others are reading: When Are Product Costs Matched Directly with Sales Revenue

Optum Rx has expanded its network to cover over 60,000 pharmacies across the US, making it one of the largest pharmacy networks in the country.

The company has also introduced a new program to help patients save money on their prescriptions, offering discounts on certain medications and free shipping on online orders.

This expansion and new program demonstrate Optum Rx's commitment to making prescription medication more accessible and affordable for its customers.

You might enjoy: Carefirst Rx

Optum Rx has made a significant move to simplify access to consumer drugs by eliminating reauthorization requirements for over 140 chronic disease medications, including products for HIV, behavioral health, and hypertension.

This decision was made by Optum Rx's Pharmacy and Therapeutics Committee, which consists of practicing physicians and pharmacists.

The committee identified these products as drugs for which reauthorizations would provide only minimal value.

Chronic conditions affect about 60% of Americans and are the leading cause of death in the United States.

Optum Rx aims to eliminate up to 25% of reauthorizations, which is equivalent to more than 10% of overall pharmacy prior authorizations.

This initiative started with about 80 drugs and has room to expand the list over time.

For drugs like those for cystic fibrosis, once a genetic condition is confirmed through testing, there is minimal additional value in reauthorizing an effective, lifelong treatment.

Readers also liked: Optum Bank Hsa Investment Options

Optum Rx has introduced a new cost-based pharmacy reimbursement model that will pay pharmacies more for brand-name drugs and less for generics.

This change is intended to reduce variation in how pharmacies are paid and better align with the costs pharmacies face due to manufacturer pricing actions.

The model will begin immediately and be fully implemented by January 2028, affecting more than 24,000 independent community pharmacies.

The new reimbursement model is designed to provide pharmacies with better financial means to stock more medicines, which is expected to alleviate drug shortages and improve medication access.

By partnering with Epic Pharmacy Network (EPN), a Pharmacy Services Administrative Organization representing over 1,000 independent pharmacies, Optum Rx aims to make medications more affordable for consumers.

The cost-based reimbursement model is a response to the industry-wide pharmacy model's limitations, which were designed to promote the use of more affordable generics but have since been hindered by the rise of high-cost branded drugs.

Optum Rx CEO Patrick Conway has stated that this move will help correct imbalances in how pharmacies are paid for brand and generic drugs and ensure greater access to medicines for patients across the country.

The new reimbursement model is part of a larger trend in the industry, with CVS Health's CostVantage model and other companies introducing cost-plus drug plans to provide more simplicity and transparency in pharmacy reimbursement.

Recommended read: Better than Cash Alliance

Physicians argue that prior authorization increases paperwork burden and delays care plans, which can have severe health outcomes for patients.

A number of major payers, including Optum Rx's sister company UnitedHealthcare and CVS-owned Aetna, have rolled back prior authorizations in the past few years.

Doctors say more reform is needed, especially as payers automate prior authorization processes, sparking concerns about algorithms driving improper denials.

Reauthorizations are occasionally necessary to ensure the ongoing use of a drug is safe, but for many drugs, there is "minimal additional value" in reauthorization, according to Optum Rx.

Drugs included in the program don't present an added safety risk for patients and have established long-term effectiveness and constant dose requirements.

Patients using the drugs also have to have an established diagnosis of a chronic condition, and have considered alternative therapy for authorization to be waived.

Here's a breakdown of the types of drugs included in the program:

Optum Rx's move to eliminate reauthorizations is a savvy PR move, as it seeks to improve its public image amidst criticism from lawmakers and regulators.

Curious to learn more? Check out: Move 401k to 403b

Optum Rx is making a big change to help patients and doctors. They're eliminating prior authorizations on dozens of drugs.

Starting May 1, Optum Rx will eliminate reauthorizations for roughly 80 drugs. This means that doctors won't have to get approval from a patient's health or drug plan before continuing to prescribe these medications.

The drugs included in this program treat high cholesterol, lung disease, multiple sclerosis, migraines, and more. These are serious conditions that require ongoing treatment.

Optum Rx says that they plan to apply this policy to additional drugs in the future. They're looking for drugs that don't present an added safety risk for patients and have established long-term effectiveness.

Here's a list of some of the conditions and medications included in the program:

This change is a result of pressure from doctors and patients who have experienced delays and complications due to prior authorizations.